{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-065305","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.096652+00:00","generated_at":"2026-06-11T19:37:29.120764+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cadrenal Therapeutics Q2 2023 update; cash $9.6M, tecarfarin expansion into LVADs","bullets":["Q2 2023 operating expenses (excl. non-cash) totaled $835,000; cash balance $9.6M as of Aug 14.","Completed $7.5M private placement at $1.75 per share with an institutional investor.","Expanded tecarfarin development to LVAD patients; estimated $600M annual U.S. addressable market.","Appointed cardiovascular executive Robert Lisicki to the board of directors.","Combined addressable market for ESKD/AFib and LVADs estimated at $1.6B annually in U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-065305","json":"https://secwatch.observer/filing/0001213900-23-065305.json","markdown":"https://secwatch.observer/filing/0001213900-23-065305.md","text":"https://secwatch.observer/filing/0001213900-23-065305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023065305/0001213900-23-065305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023065305/ea183225-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:37:29.120764+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c5942a74bb3e92e45540ca458d5abe31522e89f","claim":"Cadrenal Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"issued a press release that included financial information for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023065305/0001213900-23-065305-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}